Proliferative Diabetic Retinopathy (PDR) Market Forecast and Insights: Exploring Growth Trends, Market Size, and Emerging Opportunities
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Proliferative Diabetic Retinopathy (PDR) Market?
The proliferative diabetic retinopathy (PDR) market is projected to grow due to the increasing rates of diabetes. Diabetes, a chronic disease marked by high blood sugar levels, is the primary cause of proliferative diabetic retinopathy. There are several treatment options available to prevent further damage to the retina and maintain visual health. For example, data from the National Health Service (NHS) indicates a rise in diabetes cases amongst individuals under 40, from 173,166 in 2022 to 216,440 in 2023. This sharp increase underscores an alarming trend in this age demographic and reveals a quick rise in diabetes amongst the younger population. Hence, the increasing incidence of diabetes propels the proliferative diabetic retinopathy (PDR) market. The Proliferative Diabetic Retinopathy (PDR) Market is likely to see more expansion due to the growing prevalence of obesity. Obesity, a complex and chronic condition associated with excessive body fat, often leads to poor health. It is linked to insulin resistance, chronic low-grade inflammation, and increased oxidative stress, which can harm the retinal microvasculature and lead to diabetic retinopathy. As per a 2022 report by Trust for America’s Health, a US-based non-profit organization, obesity rates in the US are rising, with 40% of American adults being obese. This marks an increase from last year, as adult obesity rates have soared above 35% in 19 states, up from 16 states the previous year. Therefore, the increasing rates of obesity contribute substantially to the growth of the proliferative diabetic retinopathy (PDR) market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp
#What is the Anticipated CAGR of theProliferative Diabetic Retinopathy (PDR) Market, and What Factors Will Drive It?
The market size for proliferative diabetic retinopathy (PDR) has seen a swift increase in the recent past. It is projected to expand from $2.42 billion in 2024 to $2.7 billion in 2025, showing a compound annual growth rate (CAGR) of 11.6%. The increase during the historic period may be due to the rising occurrence of diabetes, alterations in lifestyle and unhealthy dietary habits, state policies, and a growing incidence of vision loss related to diabetes.
The market for proliferative diabetic retinopathy (PDR) is predicted to experience significant expansion in the upcoming years, with an anticipated value of $4.02 billion in 2029, representing a compound annual growth rate (CAGR) of 10.5%. Factors influencing this anticipated growth during the projected period include an aging demographic, heightened public comprehension and awareness about diabetes, funds dedicated to research and development, and increasing requirement for combined therapies. Notable trends for the projected period comprise advancements in diagnostic technologies, innovative treatment options, the use of artificial intelligence (AI) for prompt diagnosis, advancements in gene therapy, and sophisticated retinal imaging.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911
What Are the Key Market Innovations in theProliferative Diabetic Retinopathy (PDR) Market Over the Coming Years?
Top organizations involved in the proliferative diabetic retinopathy market consistently emphasize on the development of unique therapies to escalate the efficiency of treatment, decrease the hardship of treatment and augment patient results. For instance, Biogen, an American biotechnology firm, in collaboration with Samsung Bioepis, a biotech firm from South Korea, launched Byooviz (ranibizumab-nuna) in the United States, making it the first ophthalmology biosimilar in the country, in June 2022. These products are applied in the treatment of individuals suffering from diabetic macular edema, proliferative diabetic retinopathy, wet AMD (neovascular age-related macular degeneration), and choroidal neovascularization.
Who Are the Top Companies Driving Innovation and Growth in theProliferative Diabetic Retinopathy (PDR) Market?
Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.
Order Your Report Now For A Swift Delivery:
Which Key Market Segments Comprise the Proliferative Diabetic Retinopathy (PDR) Market and Drive Its Revenue Growth?
The proliferative diabetic retinopathy (PDR) market covered in this report is segmented –
1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy
2) By Mode of Administration: Injectables, Oral, Other Mode Of Administrations
3) By Application: Hospitals, Clinics, Other Applications
Subsegments:
1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab
2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12911&type=smp
Which Regions Are Emerging as Leaders in the Proliferative Diabetic Retinopathy (PDR) Market?
North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Reports Similar to the Global Proliferative Diabetic Retinopathy (PDR) Market 2025, By The Business Research Company:
Pet Diabetes Care Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/pet-diabetes-care-devices-global-market-report
Insulin Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report
Smart Insulin Pens Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
